Table 1 Patient variables and clinical... | American Society of Hematology

Table 1

Patient variables and clinical outcome stratified by INPP4B expression

	Overall population		INPP4B high (50%-100%)		INPP4B low (<50%)		P
	No.	%	No.	%	No.	%	P
Total No. of patients	205		25		180
Age, y							.22
Median	55.9		60.4		54.6
Range	16.7-78.4		22.7-73.5		16.7-78.4
Secondary AML		9		8		9	1
WBC × 10⁹/L							.06
Median	9.1		4.2		9.7
Range	0.1-292		1.0-77.3		0.1-292
>100 × 10⁹/L		9		0		10	.13
Karyotype (n = 195)
Favorable		9		0		10	.13
Intermediate		71		65		72	.63
Adverse		20		35		18	.09
Molecular features of intermediate-risk karyotype AML (n = 58)
NPM1^MUT		43		0		48	.03
FLT3-ITD		36		17		38	.40
NPM1^WT/FLT3^WT		45		83		40	.08
CR from first induction
All patients		62		48		64	.13
Patients <65 y (n = 162)		67		39		71	.01
Relapse-free survival, mo
Median	11.5		6.2		11.8		.01
Intermediate-risk karyotype	11.8		6.2		12.5		.05
NPM1^WT/FLT3^WT	10.3		6.2		13.1		<.01
Adverse karyotype	6.0		5.9		8.1		.34
Overall survival, mo
Median	22.8		11.5		26.6		<.01
Intermediate karyotype	25.1		13.2		27.1		<.01
NPM1^WT/FLT3^WT	NR		6.8		NR		<.01
Adverse karyotype	11.0		10.7		11.0		.19

	Overall population		INPP4B high (50%-100%)		INPP4B low (<50%)		P
	No.	%	No.	%	No.	%	P
Total No. of patients	205		25		180
Age, y							.22
Median	55.9		60.4		54.6
Range	16.7-78.4		22.7-73.5		16.7-78.4
Secondary AML		9		8		9	1
WBC × 10⁹/L							.06
Median	9.1		4.2		9.7
Range	0.1-292		1.0-77.3		0.1-292
>100 × 10⁹/L		9		0		10	.13
Karyotype (n = 195)
Favorable		9		0		10	.13
Intermediate		71		65		72	.63
Adverse		20		35		18	.09
Molecular features of intermediate-risk karyotype AML (n = 58)
NPM1^MUT		43		0		48	.03
FLT3-ITD		36		17		38	.40
NPM1^WT/FLT3^WT		45		83		40	.08
CR from first induction
All patients		62		48		64	.13
Patients <65 y (n = 162)		67		39		71	.01
Relapse-free survival, mo
Median	11.5		6.2		11.8		.01
Intermediate-risk karyotype	11.8		6.2		12.5		.05
NPM1^WT/FLT3^WT	10.3		6.2		13.1		<.01
Adverse karyotype	6.0		5.9		8.1		.34
Overall survival, mo
Median	22.8		11.5		26.6		<.01
Intermediate karyotype	25.1		13.2		27.1		<.01
NPM1^WT/FLT3^WT	NR		6.8		NR		<.01
Adverse karyotype	11.0		10.7		11.0		.19

FLT3, Fms-like tyrosine kinase 3; MUT, mutant; NPM1, nucleophosmin 1; NR, not reached; WBC, white blood cell count; WT, wild-type.